# Revolution Medicines, Inc. (RVMD) FY2024 Q1 Balance Sheet

- Company: Revolution Medicines, Inc. (RVMD)
- Period: As of 2024-03-31
- Filing: Q1 FY2024 10-Q, filed 2024-05-08, accession number 0000950170-24-055655
- Page: https://plicit.ai/financials/rvmd/fy2024-q1-balance-sheet
- Chart image: https://plicit.ai/charts/rvmd-fy2024-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,908,362,000 US dollars
- **Current assets**: 1,729,202,000 US dollars
- **Non-current assets**: 179,160,000 US dollars
- **Liabilities**: 182,895,000 US dollars
- **Current liabilities**: 93,723,000 US dollars
- **Non-current liabilities**: 89,172,000 US dollars
- **Equity**: 1,725,467,000 US dollars
- **Marketable securities**: 1,415,108,000 US dollars
- **Cash and cash equivalents**: 288,432,000 US dollars
- **Prepaid expenses and other current assets**: 25,662,000 US dollars
- **Accounts receivable**: 0 US dollars
- **Operating lease right-of-use asset**: 76,193,000 US dollars
- **Intangible assets, net**: 57,472,000 US dollars
- **Property and equipment, net**: 23,697,000 US dollars
- **Goodwill**: 14,608,000 US dollars
- **Other noncurrent assets**: 4,159,000 US dollars
- **Restricted cash**: 3,031,000 US dollars
- **Accrued expenses and other current liabilities**: 53,175,000 US dollars
- **Accounts payable**: 32,379,000 US dollars
- **Operating lease liability, current**: 8,169,000 US dollars
- **Operating lease liability, noncurrent**: 79,860,000 US dollars
- **Warrant liabilities**: 3,157,000 US dollars
- **Deferred tax liability**: 3,115,000 US dollars
- **Other noncurrent liabilities**: 3,040,000 US dollars
- **Additional paid-in capital**: 2,980,360,000 US dollars
- **Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 170,473,067 and 170,234,594 shares issued as of March 31, 2024 and December 31, 2023, respectively; 164,913,014 and 164,674,594 shares outstanding as of March 31, 2024 and December 31, 2023, respectively**: 16,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; none issued and outstanding at March 31, 2024 and December 31, 2023, respectively**: 0 US dollars
- **Accumulated deficit**: negative 1,253,711,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 1,198,000 US dollars
- **Gross equity (calculated)**: 2,980,376,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.